Thrivent Financial for Lutherans Increases Stock Holdings in Repligen Corporation $RGEN

Thrivent Financial for Lutherans grew its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 6.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 458,820 shares of the biotechnology company’s stock after purchasing an additional 28,716 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.82% of Repligen worth $61,331,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of RGEN. Rhenman & Partners Asset Management AB boosted its position in shares of Repligen by 333.3% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock valued at $2,425,000 after purchasing an additional 15,000 shares during the period. XTX Topco Ltd lifted its stake in Repligen by 34.1% in the second quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock valued at $2,158,000 after buying an additional 4,417 shares during the last quarter. Delta Investment Management LLC acquired a new stake in shares of Repligen in the third quarter valued at approximately $6,779,000. Congress Asset Management Co. grew its position in shares of Repligen by 43.4% during the third quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock worth $29,219,000 after acquiring an additional 66,142 shares during the last quarter. Finally, Blue Whale Capital LLP acquired a new position in shares of Repligen in the 2nd quarter valued at $35,782,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Down 4.5%

Repligen stock opened at $149.37 on Monday. The stock’s 50 day moving average price is $164.37 and its 200 day moving average price is $144.24. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $175.77. The company has a market cap of $8.41 billion, a PE ratio of 7,472.24, a price-to-earnings-growth ratio of 2.71 and a beta of 1.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Evercore ISI increased their price target on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Canaccord Genuity Group upped their price objective on Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Wednesday, October 29th. Finally, Barclays lifted their target price on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $179.62.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 25,000 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $156.88, for a total transaction of $3,922,000.00. Following the sale, the director owned 100,743 shares of the company’s stock, valued at approximately $15,804,561.84. The trade was a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO James Bylund sold 2,191 shares of the company’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares in the company, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 49,657 shares of company stock valued at $7,721,077 in the last ninety days. 1.20% of the stock is currently owned by company insiders.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.